Listen as our experts explore the clinical evidence supporting gene therapies as a new form of durable treatment for nAMD. Discover how these therapies are designed to provide prolonged VEGF suppression and what early clinical data reveal about their efficacy and safety. Hear first-hand perspectives on which patients are the best candidates, the skills needed to deliver these therapies, and posttreatment monitoring requirements.
Gene Therapy for nAMD: Navigating the Next Era of Durable Retinal Treatment
7
episodes
52m
Details
Presenters
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Evolve Medical Education, LLC requires all faculty and planners to disclose financial relationships with ineligible companies. All relevant financial relationships have been reviewed and mitigated to ensure that the content is free from commercial bias.
The following faculty and planners have disclosed relevant financial relationships with ineligible companies in the past 24 months.
Szilárd Kiss, MD, FASRS
Professor of Ophthalmology
Weill Cornell University
New York, NYConsulting Fees: Beacon Therapeutics, Eli Lilly, Regeneron
Carl Regillo, MD
Professor of Ophthalmology
Wills Eye Hospital, Thomas Jefferson University
Philadelphia, PAConsulting Fees: 4D Molecular Therapeutics, Adverum Biotechnologies, Alcon, Allergan, Amgen, Annexon, Apellis Pharmaceuticals, Aviceda Therapeutics, Bausch + Lomb, BioCryst Pharmaceuticals, Boehringer Ingelheim, Breye Therapeutics, Chengdu Kanghong Pharmaceutical Group, Clearside Biomedical, Cognition Therapeutics, Endogena Therapeutics, EyePoint Pharmaceuticals, Genentech, Iveric Bio, Janssen, jCyte, Kodiak Sciences, Kyoto Drug Discovery & Development, Lineage Cell Therapeutics, Merck, Nanoscope Therapeutics, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Novelty Nobility, Ocuphire Pharma, Ocugen, OcuTerra Therapeutics, ONL Therapeutics, Opthea, Outlook Therapeutics, Ray Therapeutics, RegenxBio, Sanofi, Stealth BioTherapeutics, Théa Pharma, ZEISS, ZipBio
Research: 4D Molecular Therapeutics, Adverum Biotechnologies, Alcon, Allergan, Annexon, Apellis Pharmaceuticals, Astellas Pharma, Applied Genetic Technologies Corporation, EyeBio, EyePoint Pharmaceuticals, Genentech, Janssen, Kodiak Sciences, Lineage Cell Therapeutics, NGM Biopharmaceuticals, Novartis, Ocugen, OcuTerra Therapeutics, Opthea, Regeneron, RegenxBio, Stealth BioTherapeutics
Stock Ownership: Aviceda Therapeutics, OcugenLejla Vajzovic, MD, FASRS
Professor of Ophthalmology
Duke University Eye Center
Durham, NCConsulting Fees: AbbVie, Alcon, Alimera, Apellis, Astellas, Bausch + Lomb, Beaver-Visitec, BMC, Clearside, Coherus Biosciences, DORC, Genentech/Roche, GuidePoint, Gyroscope, Janssen, Novartis, Ocugen, Ocular Therapeutix, Oculus Surgical, OcuTerra, Outlook, RegenxBio
Investigator: AGTC, Alcon, Aldeyra, Genentech/Roche, Heidelberg, NEI, Novartis, Ocular Therapeutix, RegenxBio
Research: Gyroscope, HeidelbergReviewers/Planners/Authors:
- Sandra Hannaford has no relevant relationships to disclose.
- Stephanie Wenick, MPhil, has served as a consultant medical writer for Nanoscope Therapeutics
- Daniel Olson, MD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Identify patients with neovascular age-related macular degeneration (nAMD) who are at high risk of fluid fluctuations that may lead to retinal damage
- Discuss mechanisms of action, methods of delivery, efficacy, and safety data for nAMD
- Assess route-, dose-, and prophylaxis-related contributors to adverse event risk with emerging gene therapies for nAMD
- Evaluate procedural techniques for gene therapy delivery in nAMD
Target Audience
This activity has been designed to meet the educational needs of retina specialists and ophthalmologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with nAMD.
Accreditation and Credit Designation Statements
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Evolve Medical Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Evolve Medical Education LLC (Evolve) is a leader in cultivating healthcare for patients by educating clinical competence of the healthcare team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.
Commercial Support
This activity is supported by an independent educational grant from Eli Lilly.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
